Novel anticancer drug discovery
References and recommended reading (61)
- et al.
Current strategies on discovery of anticancer drugs in the United States of America
Saishin Igaku
(1998) - et al.
Tyrosine kinase assays adapted to homogenous time-resolved fluorescence
Drug Discov Today
(1998) - et al.
A synthetic inhibitor of the mitogen-activated protein kinase cascade
- et al.
New drugs on the horizon: matrix metalloproteinase inhibitors
The Oncologist
(1998) - et al.
Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines
Anticancer Res
(1998) - et al.
Design synthesis and biological evaluation of nonpeptide integrin antagonists
Bioorg Med Chem
(1998) Molecular target therapy of cancer Cancer genes and cancer regulating genes
Kagaku Ryo no Ryoiki
(1998)- et al.
Genomics and the discovery of new drug targets
Curr Opin Chem Biol
(1999) - et al.
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
Science
(1998) - et al.
Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C
Science
(1998)
Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1
Nature
(1998)
Increasing complexity of Ras signal transduction: involvement of Rho family proteins
Adv Cancer Res
(1998)
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands
Biochim Biophys Acta
(1998)
The development of monoclonal antibodies for the therapy of cancer
Crit Rev Eukaryot Gene Exp
(1998)
Augmentation of of a humanized anti HER2 mAB 4D5 induced growth inhibition by human-mouse chimeric anti-EGF receptor mAB C225
Oncogene
(1998)
2-Substituted aminopyrido[23-d]pyrimidin-7 (8H) -ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity
J Med Chem
(1998)
Development of a binding model of protein tyrosine kinase for substituted pyrido[2,3-d]pyrimidine inhibitors
J Med Chem
(1998)
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
Cancer Res
(1999)
Potent inhibitors of Grb2 SH2 domain binding by non-phosphate-containing ligands
J Med Chem
(1999)
The structural basis of the activation of Ras by Sos
Nature
(1998)
Acquisition of high-affinity SH2-targeted ligands via a spatially focused library
J Med Chem
(1999)
Pre-clinical development of farnesyltransferase inhibitors
Cancer Metastasis Rev
(1998)
Inhibitors of farnesyl protein transferase. 4-amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl) piperazine and 1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl) piperazine
J Med Chem
(1998)
Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity
J Med Chem
(1998)
Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate
Biochemistry
(1998)
Non-Ras targets of farnesyltransferase inhibitors: focus on Rho
Oncogene
(1998)
Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating Ras oncogenes
Cancer Res
(1998)
Oncoprotein networks
Cell
(1997)
First-and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies
Anticancer Drug Des
(1997)
Protein kinase C: a worthwhile target for anticancer drugs?
Anticancer Drugs
(1997)
Cited by (0)
Copyright © 1999 Published by Elsevier Ltd.